Association of White Matter Hyperintensity Markers on MRI and Long-term Risk of Mortality and Ischemic Stroke

The SMART-MR Study

Rashid Ghaznawi, MD, MSc, Mirjam I. Geerlings, PhD, Myriam Jaarsma-Coes, MSc, Jeroen Hendrikse, MD, PhD, and Jeroen de Bresser, MD, PhD, on behalf of the UCC-Smart Study Group

Neurology® 2021;96:e2172-e2183. doi:10.1212/WNL.0000000000011827

Abstract

Objective

To determine whether white matter hyperintensity (WMH) markers on MRI are associated with long-term risk of mortality and ischemic stroke.

Methods

We included consecutive patients with manifest arterial disease enrolled in the Second Manifestations of Arterial Disease–Magnetic Resonance (SMART-MR) study. We obtained WMH markers (volume, type, and shape) from brain MRI scans performed at baseline using an automated algorithm. During follow-up, occurrence of death and ischemic stroke was recorded. Using Cox regression, we investigated associations of WMH markers with risk of mortality and ischemic stroke, adjusting for demographics, cardiovascular risk factors, and cerebrovascular disease.

Results

We included 999 patients (59 ± 10 years; 79% male) with a median follow-up of 12.5 years (range 0.2–16.0 years). A greater periventricular or confluent WMH volume was independently associated with a greater risk of vascular death (hazard ratio [HR] 1.29, 95% confidence interval [CI] 1.13–1.47) for a 1-unit increase in natural log-transformed WMH volume and ischemic stroke (HR 1.53, 95% CI 1.26–1.86). A confluent WMH type was independently associated with a greater risk of vascular (HR 1.89, 95% CI 1.15-3.11) and nonvascular death (HR 1.65, 95% CI 1.01–2.73) and ischemic stroke (HR 2.83, 95% CI 1.36-5.87). A more irregular shape of periventricular or confluent WMH, as expressed by an increase in concavity index, was independently associated with a greater risk of vascular (HR 1.20, 95% CI 1.05–1.38 per SD increase) and nonvascular death (HR 1.21, 95% CI 1.03–1.42) and ischemic stroke (HR 1.28, 95% CI 1.05–1.55).

Conclusions

WMH volume, type, and shape are associated with long-term risk of mortality and ischemic stroke in patients with manifest arterial disease.
White matter hyperintensities (WMH) of presumed vascular origin are frequently observed in older individuals on brain MRI and are an important cause of cognitive decline and dementia. They are considered hallmark features of cerebral small vessel disease (CSVD). WMH are heterogeneous lesions that correspond to different underlying brain parenchymal changes. Previous studies on CSVD mainly focused on WMH volume as a marker for CSVD severity. However, there is evidence to suggest that other markers of WMH may also provide clinically relevant information on severity and prognosis of CSVD. Specifically, histopathologic studies reported that smooth and periventricular WMH are associated with mild changes of the brain parenchyma, whereas irregular and confluent WMH are associated with more severe parenchymal changes, including loss of myelin and incomplete parenchymal destruction. We previously developed an automated MRI method to assess in vivo advanced WMH markers (volume, type, and shape). Using this algorithm, we reported differences in advanced WMH markers such as shape in frail elderly patients, patients with diabetes mellitus, and patients with lacunes on MRI. These findings suggest that advanced WMH MRI markers may provide clinically important information on CSVD severity.

The relationship between advanced WMH markers and long-term clinical outcomes, however, is not clear. Examining this relationship is of importance as WMH markers may aid in future patient selection for preventive treatment to ameliorate the risk of CSVD-related death and ischemic stroke. Therefore, in the present study, we aimed to assess whether WMH volume, type, and shape were associated with greater risk of mortality (including vascular death) and ischemic stroke in patients with manifest arterial disease over 12 years of follow-up.

Methods
Standard Protocol Approvals, Registrations, and Patient Consents

The Second Manifestations of Arterial Disease–Magnetic Resonance (SMART-MR) study was approved by the medical ethics committee of the University Medical Center Utrecht according to the guidelines of the Declaration of Helsinki of 1975. Written informed consent was obtained from all patients participating in the SMART-MR study.

Study Population

We used data from the SMART-MR study. The SMART-MR study is a prospective cohort study at the University Medical Center Utrecht with the aim of investigating risk factors and consequences of brain changes on MRI in patients with manifest arterial disease. A total of 1,309 middle-aged and older adult patients referred to our medical center for treatment of manifest arterial disease (cerebrovascular disease, manifest coronary artery disease, abdominal aortic aneurysm, or peripheral arterial disease) were included for baseline measurements between 2001 and 2005. During a 1-day visit to the University Medical Center Utrecht, ultrasonography of the carotid arteries to measure the intima-media thickness (mm), blood and urine samplings, a physical examination, neuropsychological assessment, and a 1.5T brain MRI scan were performed. We used questionnaires for the assessment of demographics, medical history, risk factors, medication use, and cognitive and physical functioning.

Vascular Risk Factors

We assessed age, sex, smoking habits, and alcohol intake at baseline using questionnaires. The body mass index (BMI) was calculated (kg/m²) by measuring weight and height. We measured systolic blood pressure (mm Hg) and diastolic blood pressure (mm Hg) 3 times with a sphygmomanometer and the average of these measurements was calculated. Hypertension was defined as a mean systolic blood pressure of >160 mm Hg, a mean diastolic blood pressure of >95 mm Hg, or the self-reported use of antihypertensive drugs. To determine glucose and lipid levels, an overnight fasting venous blood sample was taken. We defined diabetes mellitus as a fasting serum glucose level of ≥7.0 mmol/L or use of glucose-lowering medication or a known history of diabetes. The degree of carotid artery stenosis at both sides was assessed with color Doppler-assisted duplex scanning using a 10 MHz linear-array transducer (ATL Ultramark 9). Blood flow velocity patterns were used to evaluate the severity of carotid artery stenosis and the greatest stenosis observed on the left or right side of the common or internal carotid artery was taken to determine the severity of carotid artery disease. We defined a carotid artery stenosis ≥70% as a peak systolic velocity ≥210 cm/s.

Brain MRI

MRI of the brain was performed on a 1.5T whole-body system (Gyrosan ACS-NI; Philips Medical Systems, Best, the Netherlands) using a standardized scan protocol. Transversal fluid-attenuated inversion recovery (FLAIR) (repetition time [TR] 6,000 ms; echo time [TE] 100 ms; inversion time [TI] 2,000 ms), T1-weighted (TR 235 ms; TE 2 ms), T1-weighted inversion recovery (TR 2,900 ms; TE 22 ms; TI 410 ms), and T2-weighted images (TR 2,200 ms; TE 11 ms) were acquired with a voxel size of 1.0 × 1.0 × 4.0 mm³ and
contiguous slices. A neuroradiologist blinded to patient characteristics visually rated brain infarcts on the T1-weighted, T2-weighted, and FLAIR images of the MRI scans. We defined lacunes as focal lesions between 3 and 15 mm according to the STRIVE criteria. Nonlacunar lesions were categorized into large infarcts (i.e., cortical infarcts and subcortical infarcts not involving the cerebral cortex) and those located in the brainstem or cerebellum.

**WMH Volumes**

WMH and brain volumes (intracranial volume and total brain volume) were obtained using the \( k \)-nearest neighbor (kNN) automated segmentation program on the T1-weighted, FLAIR, and T1-weighted inversion recovery sequences of the MRI scans. We defined lacunes as focal lesions between 3 and 15 mm according to the STRIVE criteria. Nonlacunar lesions were categorized into large infarcts (i.e., cortical infarcts and subcortical infarcts not involving the cerebral cortex) and those located in the brainstem or cerebellum.

**WMH Types**

We categorized patients into the following 3 WMH types: periventricular WMH type without deep WMH, periventricular WMH type with deep WMH, and a confluent WMH type. We did not categorize the latter type according to presence or absence of deep WMH as the number of patients with a confluent WMH without deep WMH (\( n = 5 \)) was insufficient to perform statistical analyses.

**WMH Shape Markers**

We hypothesized that a more irregular shape of WMH may indicate more severe cerebral parenchymal damage based on previous histopathologic studies. The degree to which deep WMH are punctiform or ellipsoidal may also provide information on CSVD severity.

Irregularity of periventricular or confluent WMH was quantified using the concavity index and fractal dimension. In
previous work, we established that the concavity index was a robust shape marker that showed a normal distribution in the study sample and provided information on WMH shape irregularity based on volume and surface area.\textsuperscript{14,24} The concavity index was calculated by reconstructing convex hulls and calculating volume and surface area ratios of lesions, in which a higher concavity index value corresponds to a more irregular shape of periventricular or confluent WMH.\textsuperscript{14} Fractal dimension was calculated using the box counting method and was used to quantify irregularity of periventricular or confluent WMH and of deep WMH.\textsuperscript{14,25,26} A higher fractal dimension value indicated a more irregular WMH shape. As patients frequently show multiple deep WMH, a mean value for the fractal dimension was calculated across all deep WMH per patient.

The degree to which deep WMH are punctiform or ellipsoidal was assessed using the eccentricity, which was calculated by dividing the minor axis of a deep WMH lesion by its major axis.\textsuperscript{14,15} A high eccentricity value corresponded to a

---

### Table 1 Baseline Characteristics of the Study Sample (n = 999)

| Characteristics                         | Values       |
|-----------------------------------------|--------------|
| Age, y                                  | 59 ± 10      |
| Sex, % men                              | 79.0         |
| BMI, kg/m\(^2\)                         | 27 ± 4       |
| Smoking, pack-years*                    | 18 (0, 50)   |
| Alcohol intake, % current               | 74           |
| Hypertension, %                         | 51           |
| Diabetes mellitus, %                    | 20           |
| Infarcts on MRI, %                      |              |
| Large                                   | 12           |
| Cerebellar                              | 4            |
| Brainstem                               | 2            |
| Lacunes                                 | 19           |
| WMH volumes, mL*                        |              |
| Total                                   | 0.9 (0.2, 6.4)|
| Periventricular or confluent            | 0.7 (0.1, 5.3)|
| Deep                                    | 0.1 (0.0, 0.8)|
| WMH types, %                            |              |
| Periventricular                         | 78           |
| With deep                               | 42           |
| Without deep                            | 36           |
| Confluent                               | 22           |
| WMH shape markers                       |              |
| Periventricular or confluent            |              |
| Concavity index                         | 1.06 ± 0.11  |
| Fractal dimension                       | 1.24 ± 0.22  |
| Deep                                    |              |
| Eccentricity                            | 0.48 ± 0.14  |
| Fractal dimension                       | 1.45 ± 0.15  |

Abbreviations: BMI = body mass index; WMH = white matter hyperintensities. Characteristics are presented as mean ± SD or %. * Median (10th percentile, 90th percentile).
punctiform deep WMH lesion, whereas a low value corresponded to an ellipsoidal lesion.27,28 A mean value for the eccentricity was calculated across all deep WMH per patient.

Clinical Outcomes
Patients received a questionnaire every 6 months to provide information on outpatient clinic visits and hospitalization.18 If a fatal or nonfatal event was reported, original source documents were obtained and reviewed to determine the cause of the event. All possible events were audited independently by 3 physicians of the end point committee.18 Follow-up of patients was performed until death, refusal of further participation, or loss to follow-up. Vascular-related death was defined as death caused by myocardial infarction, stroke, sudden death (unexpected cardiac death occurring within 1 hour after onset of symptoms, or within 24 hours given convincing circumstantial evidence), congestive heart failure, or rupture of an abdominal aortic aneurysm.18 We defined nonvascular-related death as death caused by cancer, infection, unnatural death, or death from another nonvascular cause.18 Ischemic stroke was defined as the occurrence of relevant clinical features that caused an increase in impairment of at least 1 grade on the modified Rankin Scale, with or without a new relevant ischemic lesion on brain imaging.18

Study Sample
Of the 1,309 patients included, MRI data were irretrievable for 19 patients and 239 patients had missing data of one or more MRI sequences due to logistic reasons or motion artifacts. Forty-four of the remaining 1,051 patients had unreliable brain volume data due to motion artifacts in all 3 MRI sequences. Four patients were excluded due to undersegmentation of WMH by the automated segmentation algorithm and another 4 patients were excluded because they did not have any WMH greater than 5 voxels. As a result, 999 patients were included in the current study.

Statistical Analysis
Baseline characteristics of the study sample were reported as means or percentages where applicable.

Patients were followed from the date of the MRI until ischemic stroke, death, loss to follow-up, or end of follow-up (March 2017), whichever came first. Cox proportional hazard analysis was used to estimate hazard ratios (HRs) for the occurrence of all-cause, vascular-related, and nonvascular-related death and ischemic stroke associated with WMH volumes, type, and shape markers. The proportional hazards assumption was checked by inspection of Schoenfeld
residuals. We concluded that the proportional hazards assumption was met for all covariates.

To reduce the risk of bias due to complete case analysis, we performed chained equations imputation on missing covariates to generate 10 imputed datasets using SPSS 25.0 (Chicago, IL). The Cox regression analyses were performed on the imputed datasets and the pooled results were presented. We used SAS 9.4 (SAS Institute, Cary, NC) and SPSS 25.0 (Chicago, IL) to perform the statistical analyses.

WMH Volumes and Clinical Outcomes
To assess whether WMH volumes were associated with clinical outcomes, we separately entered total, periventricular or confluent, and deep WMH volumes in a Cox regression model with age, sex, and intracranial volume as covariates and all-cause death, vascular death, nonvascular death, and ischemic stroke as outcomes. WMH volumes were natural log-transformed due to a non-normal distribution. In a second model, we in addition adjusted for large infarcts, lacunes, diastolic blood pressure, systolic blood pressure, diabetes mellitus, body mass index, and smoking pack-years at baseline. We also assessed the association between quartiles of WMH volumes (not natural log-transformed) and clinical outcomes, adjusted for all of the aforementioned covariates.

WMH Types and Clinical Outcomes
To assess whether WMH types were associated with clinical outcomes, a categorical variable with the 3 WMH types as outcomes was entered in a Cox regression model with age and sex as covariates and all-cause death, vascular-related death, nonvascular-related death, and ischemic stroke as outcomes. A periventricular WMH type without deep WMH was chosen as the reference category as this type represents the smallest WMH burden. In a second model, we in addition adjusted for the aforementioned covariates.

WMH Shape Markers and Clinical Outcomes
Z scores of WMH shape markers were calculated to facilitate comparison and these were entered in a Cox regression model with age and sex as covariates and all-cause death, vascular-related death, nonvascular-related death, and ischemic stroke as outcomes. In a second model, we in addition adjusted for the aforementioned covariates. If an association between a WMH shape marker and clinical outcome was observed, we in addition adjusted for total WMH volume to assess whether the association was independent of WMH volume.
Data Availability
For use of anonymized data, a reasonable request has to be made in writing to the study group and the third party has to sign a confidentiality agreement.

Results
Baseline characteristics of the study sample (n = 999) are shown in table 1. A total of 784 patients (78%) had periventricular WMH and 215 patients (22%) had confluent WMH. A periventricular with deep WMH type was present in 423 patients (42%) and a periventricular without deep WMH type was present in 361 patients (36%). In total, 274 patients died (149 vascular-related and 125 nonvascular-related) and 75 patients had an ischemic stroke during a median follow-up of 12.5 years (range 0.2–16.0 years; total number of person-years follow-up 11,303).

Associations Between WMH Volumes and Long-term Clinical Outcomes
Greater total WMH volume was associated with all-cause death (HR 1.32, 95% confidence interval [CI] 1.19–1.46 for a 1-unit increase in natural log-transformed total WMH volume), particularly vascular-related death (HR 1.47, 95% CI 1.29–1.68) and to a lesser extent nonvascular-related death (HR 1.15, 95% CI 0.99–1.34), as well as with ischemic stroke (HR 1.79, 95% CI 1.48–2.16), adjusted for age, sex, and total intracranial volume. These associations persisted after adjusting for cardiovascular risk factors and cerebrovascular disease (table 2).

Greater periventricular or confluent WMH volume was associated with all-cause death (HR 1.29, 95% CI 1.17–1.42), particularly vascular-related death (HR 1.43, 95% CI 1.26–1.63), and to a lesser extent with nonvascular-related death (HR 1.14, 95% CI 0.99–1.32), as well as with ischemic stroke (HR 1.73, 95% CI 1.45–2.08). These associations persisted after adjusting for cardiovascular risk factors and cerebrovascular disease (table 2).

Greater deep WMH volume was associated with all-cause death (HR 1.13, 95% CI 1.04–1.24), vascular-related death (HR 1.15, 95% CI 1.03–1.30), and more strongly with ischemic stroke (HR 1.24, 95% CI 1.05–1.46). Risk estimates slightly attenuated after adjusting for cardiovascular risk factors and cerebrovascular disease (table 2). A nonsignificant association was observed between greater deep WMH volume
and nonvascular death (HR 1.10, 95% CI 0.96–1.26), which did not change after adjusting for cardiovascular risk factors and cerebrovascular disease (table 2).

Risk of vascular-related death and ischemic stroke increased per quartile of periventricular or confluent WMH volume (figure 2). Similarly, risk of ischemic stroke increased per quartile of deep WMH volume (figure 3).

**Associations Between WMH Types and Long-term Clinical Outcomes**

Compared to a periventricular WMH type without deep WMH, a confluent WMH type was associated with a greater risk of all-cause death (HR 2.29, 95% CI 1.64–3.19), particularly vascular-related death (HR 2.81, 95% CI 1.75–4.49) and to a lesser extent nonvascular-related death (HR 1.85, 95% CI 1.15–2.98), as well as with ischemic stroke (HR 4.36, 95% CI 2.20–8.65). These associations persisted after adjusting for cardiovascular risk factors and cerebrovascular disease (table 3). Nonsignificant associations were observed between a periventricular WMH type with deep WMH and vascular-related death (HR 1.53, 95% CI 0.96–2.42) and ischemic stroke (HR 1.75, 95% CI 0.90–3.41), which attenuated after adjusting for cardiovascular risk factors and cerebrovascular disease (table 3).

**Table 3** Results of Cox Proportional Hazard Regression Analyses With White Matter Hyperintensity (WMH) Types as Independent Variables and All-Cause, Vascular-Related, and Nonvascular-Related Death and Ischemic Stroke as Dependent Variables

| WMH Type                        | Deaths or events, n | N per 1,000 person-years | Model 1, estimate (95% CI) | Model 2, estimate (95% CI) |
|---------------------------------|---------------------|--------------------------|---------------------------|---------------------------|
| **Periventricular without deep WMH (n = 360)** |
| All-cause death                 | 60                  | 13.7                     | 1 (reference)             | 1 (reference)             |
| Vascular death                  | 27                  | 6.2                      | 1 (reference)             | 1 (reference)             |
| Nonvascular death               | 33                  | 7.5                      | 1 (reference)             | 1 (reference)             |
| Ischemic stroke                 | 13                  | 3.0                      | 1 (reference)             | 1 (reference)             |
| **Periventricular with deep WMH (n = 424)** |
| All-cause death                 | 105                 | 21.5                     | 1.27 (0.92–1.75)          | 1.14 (0.82–1.58)          |
| Vascular death                  | 58                  | 11.9                     | 1.53 (0.96–2.42)          | 1.31 (0.82–2.09)          |
| Nonvascular death               | 47                  | 9.6                      | 1.06 (0.68–1.67)          | 1.01 (0.64–1.59)          |
| Ischemic stroke                 | 28                  | 5.9                      | 1.75 (0.90–3.41)          | 1.48 (0.75–2.91)          |
| **Confluent WMH (n = 215)**    |
| All-cause death                 | 109                 | 53.3                     | 2.29 (1.64–3.19)          | 1.74 (1.23–2.47)          |
| Vascular death                  | 64                  | 31.3                     | 2.81 (1.75–4.49)          | 1.89 (1.15–3.11)          |
| Nonvascular death               | 45                  | 22.0                     | 1.85 (1.15–2.98)          | 1.65 (1.01–2.73)          |
| Ischemic stroke                 | 34                  | 17.8                     | 4.36 (2.20–8.65)          | 2.83 (1.36–5.87)          |

Abbreviation: CI = confidence interval. Estimates represent hazard ratios (95% CI) for WMH types. A periventricular WMH type without deep WMH was the reference category. Model 1: adjusted for age and sex. Model 2: model 1 in addition adjusted for large infarcts on MRI, lacunes on MRI, diastolic blood pressure, systolic blood pressure, diabetes mellitus, body mass index, and smoking pack-years at baseline.

**Associations Between WMH Shape Markers and Long-term Clinical Outcomes**

A greater concavity index of periventricular or confluent WMH was associated with a greater risk of all-cause death (HR 1.30, 95% CI 1.18–1.43 per SD increase), particularly vascular-related death (HR 1.34, 95% CI 1.18–1.52) and to a lesser extent nonvascular-related death (HR 1.25, 95% CI 1.07–1.45), as well as with ischemic stroke (HR 1.47, 95% CI 1.23–1.76), adjusted for age and sex. These associations persisted after adjusting for cardiovascular risk factors and cerebrovascular disease (table 3). After in addition adjusting for total WMH volume, the association of concavity index with all-cause and nonvascular-related death persisted (HR 1.21, 95% CI 1.02–1.42; HR 1.23, 95% CI 1.02–1.49, respectively), whereas the association with vascular-related death and ischemic stroke attenuated (HR 1.11, 95% CI 0.89–1.39; HR 1.23, 95% CI 0.95–1.77, respectively).

A greater fractal dimension of periventricular or confluent WMH was associated with a greater risk of all-cause death (HR 1.33, 95% CI 1.16–1.52 per SD increase), vascular-related death (HR 1.52, 95% CI 1.27–1.82), and ischemic stroke (HR 2.06, 95% CI 1.60–2.65), adjusted for age and sex. These relationships persisted after adjusting for cardiovascular risk factors and cerebrovascular disease (table 4). After in
addition adjusting for total WMH volume, the association of fractal dimension with all-cause death, vascular-related death, and ischemic stroke attenuated (HR 1.10, 95% CI 0.93–1.30; HR 1.20, 95% CI 0.95–1.51; HR 1.09, 95% CI 0.52–2.27, respectively). A greater fractal dimension of periventricular or confluent WMH was not associated with a greater risk of nonvascular-related death (HR 1.13, 95% CI 0.92–1.37).

No associations were observed between eccentricity and fractal dimension of deep WMH and long-term clinical outcomes (table 4).

**Discussion**

In this cohort of patients with manifest arterial disease, we observed that WMH volume, type, and shape were associated with long-term clinical outcomes. Specifically, we found that a greater volume and a more irregular shape of periventricular or confluent WMH were related to a higher risk of death and ischemic stroke. A confluent WMH type was also associated with a greater risk of death and ischemic stroke. These relationships were independent of demographics, cardiovascular risk factors, and cerebrovascular disease at baseline.

Our finding that total WMH volume was related to risk of mortality and stroke is in line with previous studies. However, the associations of WMH volume subclassifications and WMH types with clinical outcomes presented in this study are novel. We found that the risk of mortality and ischemic stroke was predominantly determined by the volume of periventricular or confluent WMH, rather than the volume of deep WMH. This was supported by the observation that risk estimates for mortality and ischemic stroke were higher...
for a confluent WMH type than a periventricular WMH type
with deep WMH. A possible explanation for this finding may
be that confluent WMH represent more severe parenchymal
changes due to their relatively central location in the brain.
Previous studies showed that pathologic changes in the
smaller vessels of the brain can induce secondary ischemia,
which may be more profound in the white matter surrounding
the lateral ventricles as these regions are furthest removed
from collateral circulation.4,35 This notion may explain the
relatively strong association between a confluent WMH type
and occurrence of ischemic stroke in the present study.

To our knowledge, no previous studies reported on the lon-
gitudinal association of WMH shape with clinical outcomes. In
the present study, we observed that a more irregular shape of
periventricular or confluent WMH was related to an increased
risk of mortality and ischemic stroke, which was only partly
explained by WMH volume. An explanation for this finding
may be that CSVD consists of a heterogeneous group of small
tissue changes and a more irregular shape of WMH may indi-
cate the presence of a more severe CSVD subtype.35,36
Support for this notion is provided by histopathologic studies
that reported ischemic damage, loss of myelin, and incomplete
parenchymal destruction in more irregular shaped WMH,
whereas smooth WMH correlated with more benign patho-
logic changes such as venous congestion.6,8,13 Furthermore, a
previous study reported an association between a more irreg-
ular shape of WMH and frailty in elderly patients16 and in
previous work we showed that presence of lacunes on MRI
was related to a more irregular shape of WMH.14 These investi-
gations and the results of the present study suggest that in
addition to WMH volume, shape of WMH may represent a
clinically relevant marker in patients with WMH on MRI.

We observed that a confluent WMH type and a more irregular
shape of periventricular or confluent WMH were not only
associated with a greater risk of vascular death, but also of
nonvascular death. In previous work, we similarly reported
that presence of lacunes on MRI was related to a greater risk
of nonvascular death.37 An explanation for these findings is
that CSVD may be a marker of overall increased vulnerability
to adverse outcomes, possibly through the concomitant presen-
tce of generalized microvascular disease.3,4,35 Further stud-
ies in different cohorts are needed to confirm this hy-
thesis, but the reported associations with vascular and
nonvascular death suggest that WMH markers may be im-
portant in determining overall prognosis of patients with
manifest arterial disease.

Key strengths of the present study are the large number of
patients included, the longitudinal design, the relatively long
follow-up period, and the use of automated image processing
techniques that enabled us to examine multiple and also novel
features of WMH in relation to clinical outcomes. Further-
more, all MRI scans were visually checked and corrected if
needed to ensure that WMH segmentation and subsequent
analysis of WMH type and shape were accurate.

Limitations of this study include, first, the use of 1.5T MRI
instead of 3.0T MRI, which is likely more sensitive in
detecting small WMH lesions. Clinical 3.0T MRI scanners
were not readily available during the inclusion period of our
study, starting in 2001. Second, we did not categorize deep
WMH into lesions located directly under the cerebral cortex
(i.e., infracortical) and those located more centrally in the
subcortical white matter, which may differ in terms of etiol-
ogy.36 Third, MRI sequences were used with a relatively large
slice thickness of 4 mm, which is likely less accurate in de-
termining WMH shape markers than 3D MRI sequences. The
impact of slice thickness, however, may be less profound on
measurements of the concavity index as it is calculated by
determining volume and surface area ratios of periventricular
or confluent WMH, which are expected to remain relatively
constant.14 On the other hand, a more profound impact can
be expected on measurements of the fractal dimension, which
is directly dependent on voxel size.14 A larger slice thickness
will therefore lead to reduced information in the z-axis.
Similarly, shape determination of smaller deep WMH in the
size range of several millimeters may also be affected by a
relatively large slice thickness. Despite this limitation, how-
ever, we were able to detect associations between WMH
shape markers and clinical outcomes, suggesting that WMH
shape may represent a clinically relevant marker for occur-
rence of ischemic stroke and death.

Our findings demonstrate that WMH volume, type, and shape
are associated with long-term risk of mortality and ischemic
stroke in patients with manifest arterial disease. These find-
ings suggest that WMH markers on MRI may be useful in
determining patient prognosis and may aid in future patient
selection for preventive treatment.

Acknowledgment
The authors thank the research nurses, R. van Petersen (data
manager), and B. van Dinther (study manager).

Study Funding
Funding for this article was received as part of a grant from the
Netherlands Organization for Scientific Research–Medical
Sciences (NWO-MW: project 904-65-095). This funding
source had no role in the design, data collection, data analyses,
or data interpretation of the study or writing of the report.
Funding also was received from the European Research
Council under the European Union’s Horizon 2020 Pro-
gramme (H2020)/ERC grant agreements 637024 and 66681
(SVDSs@target).

Disclosure
The authors report no disclosures. Go to Neurology.org/N
for full disclosures.

Publication History
Received by Neurology July 5, 2020. Accepted in final form
January 28, 2021.
### Appendix 1 Authors

| Name                        | Location                                                                 | Contribution                                                                                     |
|-----------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Rashid Ghaznawi, MD, MSc    | Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht and Utrecht University, the Netherlands | Literature search, figures, data collection, MRI processing, data analysis, data interpretation and writing |
| Mirjam I. Geerlings, PhD    | Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht and Utrecht University, the Netherlands | Study design, data analysis and interpretation, critically reviewed the manuscript                 |
| Myriam Jaarsma-Coes, MSc    | Department of Radiology, Leiden University Medical Center, the Netherlands | MRI processing, data analysis, data interpretation, critically reviewed the manuscript             |
| Jeroen Hendriks, MD, PhD    | Department of Radiology, University Medical Center Utrecht and Utrecht University, the Netherlands | Critically reviewed the manuscript                                                                |
| Jeroen de Bresser, MD, PhD   | Department of Radiology, Leiden University Medical Center, the Netherlands | Study design, data interpretation, critically reviewed the manuscript                              |

### Appendix 2 The Utrecht Cardiovascular Cohort-Second Manifestations of Arterial Disease Study Group

| Name                        | Location                                                                 | Role                                      | Contribution                                                                                     |
|-----------------------------|--------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------|
| F.L.J. Visseren, MD, PhD    | University Medical Center Utrecht, Utrecht University, the Netherlands    | Chairman; co-investigator; SMART study contributor | Critical review, responsible for data integrity, responsible for endpoint adjudication            |
| F.W. Asselbergs, MD, PhD    | University Medical Center Utrecht, Utrecht University, the Netherlands    | Co-investigator; SMART study contributor   | Critical review, responsible for data integrity, responsible for endpoint adjudication            |
| H.M. Nathoe, MD, PhD        | University Medical Center Utrecht, Utrecht University, the Netherlands    | Co-investigator; SMART study contributor   | Critical review, responsible for data integrity, responsible for endpoint adjudication            |
| M.L. Bots, MD, PhD          | Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht and Utrecht University, the Netherlands | Co-investigator; SMART study contributor   | Critical review, responsible for data integrity, responsible for endpoint adjudication            |
| M.H. Emmeloet, MD, PhD      | University Medical Center Utrecht, Utrecht University, the Netherlands    | Co-investigator; SMART study contributor   | Critical review, responsible for data integrity, responsible for endpoint adjudication            |
| G.J. de Borst, MD, PhD      | University Medical Center Utrecht, Utrecht University, the Netherlands    | Co-investigator; SMART study contributor   | Critical review, responsible for data integrity, responsible for endpoint adjudication            |

### References

1. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c6666.
2. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuromaging. Lancet Neurol 2013;12:483–497.
3. Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 2015;11:157–165.
4. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuromaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–830.
5. Ostergaard L, Engedal TS, Moreton F, et al. Cerebral small vessel disease: capillary pathways to stroke and cognitive decline. J Cereb Blood Flow Metab 2016;36:302–325.
6. Goos AA, Seewaen A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126–135.
7. Fazekas F, Kleintert R, Offenhauer H, et al. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. AJNR Am J Neuroradiol 1991;12:915–921.
8. Fazekas F, Kleintert R, Offenhauer H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683–1689.
9. Schmidt R, Fazekas F, Kleintert G, et al. Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter: a comparative study between stroke patients and normal volunteers. Arch Neurol 1992;49:825–827.
1. Gouw AA, van der Flier WM, Fazekas F, et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability Study. Stroke 2008;39:1414–1420.

2. van Dijk EF, Prins ND, Vrooman HA, et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan Study. Stroke 2008;39:2712–2719.

3. Kloppenborg RP, Nederkoorn PJ, Grool AM, et al. Cerebral small-vessel disease and progression of brain atrophy: the SMART-MR study. Neurology 2012;79:2029–2036.

4. Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry 2008;64:273–280.

5. Ghaznawi R, Geerlings MI, Jaarsma-Coes MG, et al. The association between lacunes and white matter hyperintensity features on MRI: the SMART-MR study. J Cereb Blood Flow Metab 2019;39:2486–2496.

6. de Bresser J, Kuijf HJ, Zaanen K, et al. White matter hyperintensity shape and location feature analysis on brain MRI: proof of principle study in patients with diabetes. Sci Rep 2018;8:1893.

7. Kant MJ, Mutsaerts H, van Montfort SJT, et al. The association between frailty and MRI features of cerebral small vessel disease. Sci Rep 2019;9:11343.

8. Goessens BM, Visseren FJL, Kappelle LJ, et al. Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. Stroke 2007;38:1470–1475.

9. Ghaznawi R, Zwartbol MH, Zuidhoff NP, et al. Reduced parenchymal cerebral blood flow is associated with greater progression of brain atrophy: the SMART-MR study. J Cereb Blood Flow Metab 2020;40:1078–1086.

10. Aubeek P, Vincken KL, van Bochove GS, et al. Probabilistic segmentation of brain tissue in MR imaging. NeuroImage 2005;27:795–804.

11. Kempton MJ, Underwood TS, Brunton S, et al. A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: evaluation of a novel lateral ventricle segmentation method. NeuroImage 2011;58:1051–1059.

12. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987;149:351–356.

13. Fazekas F, Barkhof F, Wahlin LO, et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis 2002;13(suppl 2):31–36.

14. Liu EJ, Cashman KV, Rusted AC. Optimising shape analysis to quantify volcanic ash morphology. GeoResJ 2015;5:184–190.

15. Ghaznawi R, Zwartbol MH, Zuithoef S, et al. Reduced parenchymal cerebral blood flow is associated with greater progression of brain atrophy: the SMART-MR study. Neurology 2012;79:2029–2036.

16. Murphy K, van Ginneken B, Schilham AM, et al. A large-scale evaluation of automatic pulmonary nodule detection in chest CT using local image features and k-nearest-neighbour classification. Med Image Anal 2009;13:757–770.

17. Loizou CP, Petroudi S, Seimenis I, et al. Quantitative texture analysis of brain white matter lesions derived from T2-weighted MR images in MS patients with clinically isolated syndrome. J Neuroradiol 2015;42:99–114.

18. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–399.

19. Weinstein G, Wolf PA, Beiser AS, et al. Risk estimations, risk factors, and genetic variants associated with Alzheimer’s disease in selected publications from the Framingham Heart Study. J Alzheimers Dis 2013;33(suppl 1):S439–S454.

20. Lim JS, Hong KS, Kim GM, et al. Cerebral microbleeds and early recurrent stroke after transient ischemic attack: results from the Korean Transient Ischemic Attack Expression Registry. JAMA Neurol 2015;72:301–308.

21. Kuller LH, Arnold AM, Longstreth WT Jr, et al. White matter grade and ventricular volume on brain MRI as markers of longevity in the Cardiovascular Health Study. Neurobiol Aging 2007;28:1307–1315.

22. Hennekam MJW, Sluimer JD, Cordonnier C, et al. MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. Stroke 2009;40:492–498.

23. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010;41:600–606.

24. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.

25. Zhang L, Liu JZ, Dean D, et al. A three-dimensional fractal analysis method for quantifying white matter structure in human brain. J Neurosci Methods 2006;150:242–253.

26. Esteban EJ, Sepulcre J, de Miras JR, et al. Fractal dimension analysis of grey matter in multiple sclerosis. J Neurol Sci 2009;282:67–71.

27. Loizou CP, Petroudi S, Seimenis I, et al. Quantitative texture analysis of brain white matter lesions derived from T2-weighted MR images in MS patients with clinically isolated syndrome. J Neuroradiol 2015;42:99–114.

28. Murphy K, van Ginneken B, Schilham AM, et al. A large-scale evaluation of automatic pulmonary nodule detection in chest CT using local image features and k-nearest-neighbour classification. Med Image Anal 2009;13:757–770.

29. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–399.

30. Weinstein G, Wolf PA, Beiser AS, et al. Risk estimations, risk factors, and genetic variants associated with Alzheimer’s disease in selected publications from the Framingham Heart Study. J Alzheimers Dis 2013;33(suppl 1):S439–S454.

31. Lim JS, Hong KS, Kim GM, et al. Cerebral microbleeds and early recurrent stroke after transient ischemic attack: results from the Korean Transient Ischemic Attack Expression Registry. JAMA Neurol 2015;72:301–308.

32. Kuller LH, Arnold AM, Longstreth WT Jr, et al. White matter grade and ventricular volume on brain MRI as markers of longevity in the Cardiovascular Health Study. Neurobiol Aging 2007;28:1307–1315.

33. Hennekam MJW, Sluimer JD, Cordonnier C, et al. MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. Stroke 2009;40:492–498.

34. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010;41:600–606.

35. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.

36. Rost NS, Rahman RM, Biffi A, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology 2010;75:1670–1677.

37. Conijn MM, Kloppenborg RP, Algra A, et al. Cerebral small vessel disease and risk of death, ischemic stroke, and cardiac complications in patients with atherosclerotic disease: the Second Manifestations of Arterial Disease-Magnetic Resonance (SMART-MR) study. Stroke 2011;42:3105–3109.

38. Wiggins ME, Jones J, Tanner JJ, et al. Pilot investigation: older adults with atrial fibrillation demonstrate greater brain leukoaraiosis in infracortical and deep regions relative to non-atrial fibrillation peers. Front Aging Neurosci 2020;12:271.
Association of White Matter Hyperintensity Markers on MRI and Long-term Risk of Mortality and Ischemic Stroke: The SMART-MR Study
Rashid Ghaznawi, Mirjam I. Geerlings, Myriam Jaarsma-Coes, et al.
Neurology 2021;96:e2172-e2183 Published Online before print March 16, 2021
DOI 10.1212/WNL.0000000000011827

This information is current as of March 16, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/96/17/e2172.full

References
This article cites 37 articles, 12 of which you can access for free at:
http://n.neurology.org/content/96/17/e2172.full#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://n.neurology.org/content/96/17/e2172.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Cerebrovascular disease/Stroke
http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke
Cohort studies
http://n.neurology.org/cgi/collection/cohort_studies
Infarction
http://n.neurology.org/cgi/collection/infarction
MRI
http://n.neurology.org/cgi/collection/mri
Stroke prevention
http://n.neurology.org/cgi/collection/stroke_prevention

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise